Physician profile
Michael Edward Cobble
NPI 1992927834
$1,320,903.95
in general payments reported to CMS, 2019-2025
31 companies · $362K in 2025
The $362K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $47K · 2021: $89K · 2022: $165K · 2023: $293K · 2024: $242K · 2025: $362K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $710K · Travel and Lodging: $128K · Consulting Fee: $37K · Food and Beverage: $21K · Education: $84.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $710,198.13 |
| Travel and Lodging | $128,114.31 |
| Consulting Fee | $37,396.88 |
| Food and Beverage | $21,369.68 |
| Education | $84.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549,650.42 | 2021-2025 | Vraylar |
| Amgen INC. | $404,907.76 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $100,291.75 | 2019-2022 | |
| Novo Nordisk INC | $63,931.23 | 2019-2025 | Ozempic, Victoza, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57,136.04 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $51,394.72 | 2024-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $45,302.06 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $29,947.39 | 2019-2024 | Farxiga |
| Allergan, INC. | $15,760.19 | 2019-2021 | |
| Esperion Therapeutics, INC. | $1,594.09 | 2020-2021 | |
| Lilly USA, LLC | $147.63 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Phathom Pharmaceuticals, INC. | $86.26 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $77.51 | 2023 | |
| Novartis Pharmaceuticals Corporation | $76.81 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $70.97 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $62.33 | 2021-2022 | |
| Lucid Diagnostics INC. | $61.11 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $51.10 | 2019 | |
| Horizon Therapeutics Plc | $50.46 | 2020-2021 | |
| Vivus LLC | $49.66 | 2021 | |
| Currax Pharmaceuticals LLC | $43.08 | 2021-2024 | Contrave, Onzetra Xsail |
| Eisai INC. | $38.67 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.26 | 2023-2024 | Trulance, Xifaxan |
| Sunovion Pharmaceuticals INC. | $29.19 | 2019 | |
| Alkermes, INC. | $19.80 | 2025 | Aristada, Lybalvi |
| Inspire Medical Systems, INC. | $19.24 | 2024 | Inspire |
| Ultragenyx Pharmaceutical INC. | $18.14 | 2022 | |
| Coala Life INC | $15.71 | 2021 | |
| Radius Health, INC. | $13.01 | 2020 | |
| Glaxosmithkline, LLC. | $12.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cobble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.